Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the final results of the PUFs (Pipeline for Uncoilable or Failed Aneurysms) clinical study of its Pipeline™ embolization device"......

The Worldwide Innovative Networking (WIN) Consortium, a leader in personalized cancer medicine, today proudly announced that the Blue Cross and Blue Shield Association (BCBSA), an association of thirty-eight independent Blue Cross and Blue Shield companies, has become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, insurance and patient advocacy organizations"...

Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.1

• Published online in Circulation, results from RELY-ABLE®, the RE-LY® extension study, support long-term safety of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation
• Pradaxa® is the only novel oral anticoagulant with controlled long-term clinical trial data extending beyond 4 years of ongoing treatment
• The long-term results contribute to the growing body of data reinforcing Pradaxa® as an important advancement in the treatment of patients with atrial fibrillation compared to warfarin1

For media outside USA, UK and Canada only

• In the Phase IIb SOUND-C3 study, all but one patient achieved viral cure with faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin, without a need for interferon
• The study included challenging-to-cure patients with advanced liver disease, all of whom achieved viral cure

New data from Boehringer Ingelheim’s"...

The Air Ambulance aircraft of the Abu Dhabi Police’s Air Wing Department airlifted an Emirati woman who had sustained injuries in a traffic accident, from Ibri hospital in the Sultanate of Oman to Tawam hospital in Al Ain to receive necessary medical treatment.

This comes in line with the humanitarian missions provided by the Department to the public.

Ex US & UK Medical Media Only

Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the companies’ diabetes alliance will have a strong scientific and clinical presence at the 73rd American Diabetes Association (ADA) Scientific Sessions® in Chicago, 21–25 June, with 34 posters, abstracts and an oral presentation.

Empagliflozin*"...

For media outside USA, UK and Canada only

• In a new sub-analysis of the Phase III STARTVerso™1 and 2 trials entering patients with chronic genotype-1 HCV infection, 100% of patients in Taiwan, 86% in Korea and 85% in Japan achieved viral cure with faldaprevir+ (120mg) plus pegylated interferon alfa and ribavirin
• Up to 95% of patients met the criteria to stop all treatment after 24 weeks and over 90% of these patients went on to achieve viral cure (SVR12)

Aetna (NYSE: AET), a leading global diversified health care solutions company, has been appointed by the National Health Insurance Company (NHIC) of Qatar to support development of its capabilities for disease management and advanced analytic reporting.

“We are honored to be chosen to play a significant role in the creation of a modern, efficient and integrated health insurance system,” said Sandip Patel, head of Aetna International."......

Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for REVLIMID® (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

“There"...